|
1) Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine. 2005; 72: 41-7
|
|
|
|
2) Tanaka N, Kim JS, Newell JD, et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology. 2004; 232: 81-91
|
|
|
|
|
3) Rajasekaran A, Shovlin D, Saravanan V, et al. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5 years. J Rheumatol. 2006; 33: 1250-3
|
|
|
|
|
|
4) Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007; 175: 705-11
|
|
|
|
|
|
5) Turesson C, Matteson EL, Colby TV, et al. Increased CD4＋ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumo-nitis. Arthritis Rheum. 2005; 52: 73-9
|
|
|
|
|
|
6) Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20＋ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 2006; 54: 635-41
|
|
|
|
|
|
7) Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006; 116: 3183-94
|
|
|
|
|
|
8) Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006; 54: 38-46
|
|
|
|
|
|
9) Shimizu S, Yoshinouchi T, Niimi T, et al. Differing distributions of CXCR3- and CCR4-positive cells among types of interstitial pneumonia associated with collagen vascular diseases. Virchows Arch. 2007; 450: 51-8
|
|
|
|
|
|
10) Parambil JG, Myers JL, Aubry MC, et al. Causes and prognosis of diffuse alveolar damage diagnosed on surgical lung biopsy. Chest. 2007; 132: 50-7
|
|
|
|
|
|
11) Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. Eur Respir J. 2004; 24: 708
|
|
|
|
|
|
12) Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007; 25: 23-8
|
|
|
|
|
|
13) Ostor AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol. 2006; 33: 622-8
|
|
|
|
|
|
14) Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006; 33: 1189-93
|
|
|
|
|
|
15) Lindsay K, Melsom R, Jacob BK, et al. Acute progression of interstitial lung disease: a compli-cation of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology. 2006; 45: 1048-9
|
|
|
|
|
|
16) Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007; 34: 1151-4
|
|
|
|
|
|
17) Schoe A, van der Laan-Baalbergen NE, Huizinga TW, et al. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. Arthritis Rheum. 2006; 55: 157-9
|
|
|
|
|
|
18) Homma S, Sakamoto S, Kawabata M, et al. Comparative clinicopathology of obliterative bronchiolitis and diffuse panbronchiolitis. Respiration. 2006; 73: 481-7
|
|
|
|
|
|
19) Cortot AB, Cottin V, Miossec P, et al. Improve-ment of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. Respir Med. 2005; 99: 511-4
|
|
|
|
|
|
20) McCurry J. Japan deaths spark concerns over arthritis drug. Lancet. 2004; 363: 461
|
|
|
|
|
|
21) Scott DL. Interstitial lung disease and disease modifying anti-rheumatic drugs. Lancet. 2004; 363: 1239-40
|
|
|
|
|
|
22) Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 1435-9
|
|
|
|
|
|
23) Sakai F, Noma S, Kurihara Y, et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol. 2005; 15: 173-9
|
|
|
|
|
24) Koo LC, Clark JA, Quesenberry CP, et al. National differences in reporting‘pneumonia'and ‘pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf. 2005; 14: 775-87
|
|
|
|
|
|
25) Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum. 2007; 56: 2094-6
|
|
|
|
|
|
26) Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002; 46: 2294-300
|
|
|
|
|
|
27) Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52: 3403-12
|
|
|
|
|
|
28) Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malig-nancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006; 295: 2275-85
|
|
|
|
|
|
29) Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007; 66: 1339-44
|
|
|
|
|